Amphivena Therapeutics Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Amphivena Therapeutics's estimated annual revenue is currently $3.3M per year.(i)
  • Amphivena Therapeutics's estimated revenue per employee is $155,000

Employee Data

  • Amphivena Therapeutics has 21 Employees.(i)
  • Amphivena Therapeutics grew their employee count by -19% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.4M57-8%$53MN/A
#2
$21.2M137-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$1.6M10-17%N/AN/A
#6
$0.7M950%N/AN/A
#7
$11.5M74-12%N/AN/A
#8
$0.4M27510%$236.7MN/A
#9
$4M51-74%$160MN/A
#10
$2.3M1515%N/AN/A
Add Company

What Is Amphivena Therapeutics?

Amphivena Therapeutics, Inc. is a privately held, clinical-stage, immuno-oncology company based in South San Francisco, CA that is developing a novel platform of dual-action biologics to selectively relieve immune suppression and drive T-cell activation/polarization, to restore anti-cancer immunity in patients. The company's lead therapeutic candidate, AMV564, induces selective T-cell mediated killing of myeloid derived suppressor cells (MDSC), known to be associated with immune suppression and poor outcomes to immunotherapy. In parallel, it drives improved T cell effector function. AMV564 has exhibited an excellent clinical safety profile and combinability with checkpoint inhibition and represents a unique opportunity to bring new treatment options to cancer patients under-served by immunotherapy.

keywords:N/A

N/A

Total Funding

21

Number of Employees

$3.3M

Revenue (est)

-19%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Amphivena Therapeutics News

2022-04-20 - NaNotics LLC Appoints Dr. Curtis Ruegg as CDO/COO

NaNots™ are distinct from drug therapies in that they deplete soluble ... Dr. Ruegg served as CEO at Amphivena Therapeutics, developing new...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.6M21-32%$178.7M
#2
$1.7M22-80%$187M
#3
$3.6M230%N/A
#4
$3.6M235%N/A
#5
$3.7M240%N/A